Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1967 1
1973 1
1974 3
1975 1
1976 2
1977 3
1978 3
1979 3
1980 2
1981 6
1982 3
1983 7
1984 3
1985 5
1986 5
1987 6
1988 2
1989 3
1990 8
1991 5
1992 5
1993 5
1994 4
1995 4
1996 4
1997 8
1998 9
1999 12
2000 12
2001 23
2002 27
2003 26
2004 16
2005 35
2006 30
2007 33
2008 40
2009 44
2010 53
2011 76
2012 85
2013 81
2014 89
2015 74
2016 75
2017 92
2018 84
2019 88
2020 113
2021 142
2022 140
2023 111
2024 119

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,635 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity.
Ho WJ, Zhu Q, Durham J, Popovic A, Xavier S, Leatherman J, Mohan A, Mo G, Zhang S, Gross N, Charmsaz S, Lin D, Quong D, Wilt B, Kamel IR, Weiss M, Philosophe B, Burkhart R, Burns WR, Shubert C, Ejaz A, He J, Deshpande A, Danilova L, Stein-O'Brien G, Sugar EA, Laheru DA, Anders RA, Fertig EJ, Jaffee EM, Yarchoan M. Ho WJ, et al. Among authors: deshpande a. Nat Cancer. 2021 Sep;2(9):891-903. doi: 10.1038/s43018-021-00234-4. Epub 2021 Jul 29. Nat Cancer. 2021. PMID: 34796337 Free PMC article. Clinical Trial.
Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence.
Zhang S, Yuan L, Danilova L, Mo G, Zhu Q, Deshpande A, Bell ATF, Elisseeff J, Popel AS, Anders RA, Jaffee EM, Yarchoan M, Fertig EJ, Kagohara LT. Zhang S, et al. Among authors: deshpande a. Genome Med. 2023 Sep 18;15(1):72. doi: 10.1186/s13073-023-01218-y. Genome Med. 2023. PMID: 37723590 Free PMC article.
Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia.
Tubío-Santamaría N, Jayavelu AK, Schnoeder TM, Eifert T, Hsu CJ, Perner F, Zhang Q, Wenge DV, Hansen FM, Kirkpatrick JM, Jyotsana N, Lane SW, von Eyss B, Deshpande AJ, Kühn MWM, Schwaller J, Cammann C, Seifert U, Ebstein F, Krüger E, Hochhaus A, Heuser M, Ori A, Mann M, Armstrong SA, Heidel FH. Tubío-Santamaría N, et al. Among authors: deshpande aj. Mol Cancer. 2023 Dec 4;22(1):196. doi: 10.1186/s12943-023-01907-7. Mol Cancer. 2023. PMID: 38049829 Free PMC article.
Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment.
Widman AJ, Shah M, Frydendahl A, Halmos D, Khamnei CC, Øgaard N, Rajagopalan S, Arora A, Deshpande A, Hooper WF, Quentin J, Bass J, Zhang M, Langanay T, Andersen L, Steinsnyder Z, Liao W, Rasmussen MH, Henriksen TV, Jensen SØ, Nors J, Therkildsen C, Sotelo J, Brand R, Schiffman JS, Shah RH, Cheng AP, Maher C, Spain L, Krause K, Frederick DT, den Brok W, Lohrisch C, Shenkier T, Simmons C, Villa D, Mungall AJ, Moore R, Zaikova E, Cerda V, Kong E, Lai D, Malbari MS, Marton M, Manaa D, Winterkorn L, Gelmon K, Callahan MK, Boland G, Potenski C, Wolchok JD, Saxena A, Turajlic S, Imielinski M, Berger MF, Aparicio S, Altorki NK, Postow MA, Robine N, Andersen CL, Landau DA. Widman AJ, et al. Among authors: deshpande a. Nat Med. 2024 Jun;30(6):1655-1666. doi: 10.1038/s41591-024-03040-4. Epub 2024 Jun 14. Nat Med. 2024. PMID: 38877116 Free PMC article.
PanIN and CAF transitions in pancreatic carcinogenesis revealed with spatial data integration.
Bell ATF, Mitchell JT, Kiemen AL, Lyman M, Fujikura K, Lee JW, Coyne E, Shin SM, Nagaraj S, Deshpande A, Wu PH, Sidiropoulos DN, Erbe R, Stern J, Chan R, Williams S, Chell JM, Ciotti L, Zimmerman JW, Wirtz D, Ho WJ, Zaidi N, Thompson E, Jaffee EM, Wood LD, Fertig EJ, Kagohara LT. Bell ATF, et al. Among authors: deshpande a. Cell Syst. 2024 Aug 21;15(8):753-769.e5. doi: 10.1016/j.cels.2024.07.001. Epub 2024 Aug 7. Cell Syst. 2024. PMID: 39116880
Orodispersible Films: A Systematic Patent Review.
Gijare C, Deshpande A. Gijare C, et al. Among authors: deshpande a. Recent Pat Drug Deliv Formul. 2018;12(2):110-120. doi: 10.2174/1872211312666180509100216. Recent Pat Drug Deliv Formul. 2018. PMID: 29745346 Review.
Reply to Blot and Dinh.
Deshpande A, Rothberg MB. Deshpande A, et al. Clin Infect Dis. 2022 Mar 1;74(4):750-751. doi: 10.1093/cid/ciab545. Clin Infect Dis. 2022. PMID: 34245247 Free PMC article. No abstract available.
Drug Repositioning: A Unique Approach to Refurbish Drug Discovery.
Kale MA, Shamkuwar PB, Mourya VK, Deshpande AB, Shelke PA. Kale MA, et al. Among authors: deshpande ab. Curr Drug Discov Technol. 2022;19(1):e140122192307. doi: 10.2174/1570163818666210316114331. Curr Drug Discov Technol. 2022. PMID: 33726652 Review.
From bench to bedside: Single-cell analysis for cancer immunotherapy.
Davis-Marcisak EF, Deshpande A, Stein-O'Brien GL, Ho WJ, Laheru D, Jaffee EM, Fertig EJ, Kagohara LT. Davis-Marcisak EF, et al. Among authors: deshpande a. Cancer Cell. 2021 Aug 9;39(8):1062-1080. doi: 10.1016/j.ccell.2021.07.004. Epub 2021 Jul 29. Cancer Cell. 2021. PMID: 34329587 Free PMC article. Review.
1,635 results